Canadian guideline on HIV preexposure prophylaxis and nonoccupational postexposure prophylaxis for pharmacists

Public Health Agency of Canada. Summary: Estimates of HIV Incidence, Prevalence and Canada’s Progress on Meeting the 90-90-90 HIV targets, 2016. Available: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/summary-estimates-hiv-incidence-prevalence-canadas-progress-90-90-90.html#t2 (accessed Aug. 8, 2018).

Tan DHS Hull MW Yoong D et al . Canadian guidelines on HIV pre-exposure prophylaxis and non-occupational post-exposure prophylaxis. CMAJ 2017;189:E1448-58.

Grant RM Anderson PL McMahan V et al . Uptake of pre-exposure prophylaxis, sexual practices and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014;14:820-9.

Molina J Charreau I Spire B et al . Efficacy, safety and effect on sexual behavior of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017;4:e402-10.

Lal L Audsley J Murphy DA et al . Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS 2017;31:1709-14.

Seifert SM Glidden DV Meditz AL et al . Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis 2015;60:804-10.

Seifert SM Chen X Meditz AL et al . Intracellular tenofovir and emtricitabine anabolites in genital, rectal and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses 2016;32:981-91.

Molina JM Capitant C Spire B et al . On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237-46.

Paxton LA . Tenofovir-based HIV pre-exposure prophylaxis. Future Virol 2013;8:1207-18.

Ray AS Fordyce MW Hitchcock MJM . Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 2016;125:63-70.

Jafari A Khalili H Dashti-Khavidaki S . Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014;70:1029-40.

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (accessed Aug. 9, 2018).

Mugo NR Hong T Celum C et al . Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA 2014;312:362-71.

Mugwanya KK Hendrix CW Mugo NR et al . Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 2016;13:e1002132.

Quinn TC Wawer M Sewankambo N et al . Viral load and heterosexual transmission of human immunodeficiency virus. N Engl J Med 2000;342:921-9.

Johnson LF Lewis DA . The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008;35:946-59.

Globerman J Gogolishvili D Rourke SB . Evidence Review: HIV sexual transmission risk by people with suppressed HIV viral load. Toronto, ON: Ontario HIV Treatment Network; 2017.

Tsai C-C Emau P Follis KE et al . Effectiveness of postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine treatment for prevention of persistent simian immunodeficiency virus SIV_mne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-73.

Marzolini C Gibbons S Khoo S Back D . Cobicistat versus ritonavir boosting differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother 2016;71:1755-58.

Kiser JJ Bumpass JB Meditz AL . Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010;54:4999-5003.

Ramanathan S Mathias A Wei X et al . Pharmacokinetics of once-daily boosted elvitegravir when administered with acid reducing agents. J Acquir Immune Defic Syndr 2013;64:45-50.

Song I Borland J Arya N Wynne B Piscitelli S . Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 2015;55:490-6.

Gilead Sciences Canada. Truvada (emtricitabine, tenofovir disoproxil fumarate) [product monograph]. Mississauga, ON: Gilead Sciences Canada; 2017.

Fatkenheuer G Jessen H Stoehr A et al . PEPDar: a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis. HIV Med 2016;17:453-9.

McAllister JW Towns JM Mcnulty A et al . Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS 2017;31:1291-5.

McAllister JW Read P McNulty A et al . Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014;15:13-22.

Diaz-Brito V Leon A Knobel H et al . Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012;17:337-46.

Rabaud C Burty C Grandidier M et al . Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis 2005;40:303-5.

Burty C Pavel S Kamel G et al . Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. J Acquir Immun Def Syndr 2008;49:334-6.

Roland ME Neilands TB Krone MR et al . Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41:1507-13.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Available: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0 (accessed Aug. 9, 2018).

Health and Human Services Guideline Panels. Statement on potential safety signal in infants born to women taking dolutegravir from the HHS antiretroviral guidelines panels. May 18, 2018. Available: https://aidsinfo.nih.gov/news/2094/statement-on-potential-safety-signal-in-infants-born-to-women-taking-dolutegravir-from-the-hhs-antiretroviral-guideline-panels (accessed Jul. 24, 2018).

Centers for Disease Control and Prevention. Interim statement regarding potential fetal harm from exposure to dolutegravir-implications for HIV post-exposure prophylaxis. Available: https://www.cdc.gov/hiv/pdf/basics/cdc-hiv-dolutegravir-alert.pdf (accessed Jul. 24, 2018).

Tung E Thomas A Eichner A Shalit P . Feasibility of a pharmacist-run PrEP clinic in a community pharmacy setting. Presented at: Conference on Retroviruses and Opportunistic Infections; February 13-17, 2017; Seattle, Washington (Abstract 961).

Zabolotska IB Prestage G Holt M et al . Australian gay men who have taken non-occupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J Acquire Immune Defic Syndr 2011;58:424-8.

O’Byrne P MacPherson P Roy M Orser L . Community-based, nurse-led post-exposure prophylaxis: results and implications. Int J STD AIDS 2017;28:505-11.